Biotech Values

[iandy]

>I think they should be treating MCI or prodromal patients and treating them for up to 4 years.<

I believe treating MCI or prodromal patients was the idea behind ELDN005. I believe ELND005 was effective at inhibiting aggregation and the toxic effects of beta-amyloid but failed to meet it's endpoints. Why would bapineuzumab work on MCI or prodromal patients IF ELND005 failed? You call it a "abeta hammer". Perhaps it is having a postive effect (IF it is having any effect)due to an unintended consequence of all it's actions.